DURHAM, NC--(Marketwire - December 11, 2007) - Aldagen, Inc. today announced that researchers presented results demonstrating that the potent adult stem cell population isolated using Aldagen’s technology (ALDH(br) cells) is able to regenerate vascular function and repair liver damage in preclinical models. A total of seven abstracts related to Aldagen’s technology were presented at the 49th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia. The data presented provides further insight into the possible mechanism of action of ALDH(br) cells in Aldagen’s ongoing cardiovascular clinical studies. In addition, the data suggests a new clinical indication that Aldagen could potentially pursue.
